Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlobalData Plc
  6. News
  7. Summary
    DATA   GB00B87ZTG26

GLOBALDATA PLC

(DATA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GlobalData : Arcutis may face challenges when marketing roflumilast despite commercial advantage, says GlobalData

10/15/2021 | 04:22pm EST
15 Oct 2021
Arcutis may face challenges when marketing roflumilast despite commercial advantage, says GlobalData
Posted in Technology

Arcutis Biotherapeutics recently announced the submission of a New Drug Application (NDA) for its topical phosophodiesterase 4 (PDE4) inhibitor, roflumilast cream (ARQ-151), in the treatment of mild-to-severe plaque psoriasis (PsO). Despite having a potential commercial advantage as the first topical PDE4 inhibitor for an underserved PsO patient segment, GlobalData, a leading data and analytics company, notes that Arcutis may still face several challenges when marketing roflumilast cream.

Tiffany Chan, Immunology Analyst at GlobalData, comments: "Over the last decade, the PsO pipeline has been dominated by injectable biologics targeting moderate and severe disease, while topical therapies have strikingly lacked innovation. Recently this has begun to change with the launch of novel formulations of calcipotriene/betamethasone combination therapies, such as LEO Pharma's Enstilar foam in 2015 and EPI Health/MC2 Therapeutics' Wynzora Cream launching this past July. The late-stage PsO pipeline holds further innovation for topical therapies. If approved by the FDA, Arcutis' roflumilast would become the second PDE4 inhibitor to enter the PsO market (after Amgen's oral agent, Otezla) and the first topical PDE4 inhibitor for the disease."

The company's NDA submission is based on two pivotal Phase III studies, DERMIS-1 (NCT04211363) and DERMIS-2 (NCT04211389). Roflumilast, as a molecule, is already approved in oral tablet form (500mg) for chronic obstructive pulmonary disease, under the brand name Daliresp, which is currently marketed by AstraZeneca. The topical cream formulation by Arcutis is in development for PsO as well as atopic dermatitis.

Ms. Chan continues: "One challenge Arcutis could face is that it's not only a newcomer to the mature PsO market, but to the pharma market as a whole-topical roflumilast cream would represent the company's first marketed asset for any indication. Still, the company's reputation (or lack thereof) is not expected to impede regulatory decisions. If the company were to partner with a more established player in the PsO space such as AbbVie, Pfizer, or Janssen, it could expand its reach and obtain a stronger foothold in the market.

"Additionally, roflumilast cream is expected to be the one of two innovative branded topical therapies approved for PsO in the near future. Key opinion leaders interviewed by GlobalData anticipate that roflumilast cream will be directly competing with Dermavant's topical arylhydrocarbon receptor (Ahr) agonist, tapinarof cream, which is under regulatory review by the FDA as of August 2021."

Roflumilast, and other late-stage PsO pipeline agents (both topical and oral), signal a changing of the guard in terms of market development. Primary research conducted by GlobalData indicates that given the options of oral, subcutaneous, and topical therapies, PsO patients generally prefer topical therapies (followed by oral) and it appears that drug manufacturers are finally moving away from the biologic focus of the last decade to meet this remaining need. Historically, much of the clinical and research focus has been on treating the most severe patients but roflumilast cream and other newer drugs will finally address milder populations, which have been somewhat neglected until now.

Disclaimer

GlobalData plc published this content on 15 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 October 2021 20:21:15 UTC.


ę Publicnow 2021
All news about GLOBALDATA PLC
11/23Amazon's Visa block called out as tactic to promote Mastercard
AQ
11/18GLOBALDATA : Global deal activity down by 5.7% in October 2021, finds GlobalData
PU
11/18GLOBALDATA : AMETEK's job adverts double in 2021 as it prepares to expand into new markets..
PU
11/18Slovenia could become the adventure tourism capital of Europe, says GlobalData
AQ
11/18GLOBALDATA : Thailand's hot drinks sector to reach US$2.2bn by 2025, says GlobalData
PU
11/18GLOBALDATA : South Korean hot drinks market to reach US$3bn by 2025, forecasts GlobalData
PU
11/18GLOBALDATA : Hot drinks sector of Philippines to reach US$2.4bn by 2025, forecasts GlobalD..
PU
11/18GLOBALDATA : Psilocybin has potential to become a breakthrough therapy for treatment-resis..
PU
11/18GLOBALDATA : Hot drinks market of Malaysia to reach US$2bn by 2025, says GlobalData
PU
11/18GLOBALDATA : Indonesia's hot drinks market to reach US$3.1bn by 2025, forecasts GlobalData
PU
More news
Financials
Sales 2021 190 M 253 M 253 M
Net income 2021 26,3 M 35,0 M 35,0 M
Net Debt 2021 64,8 M 86,4 M 86,4 M
P/E ratio 2021 69,2x
Yield 2021 1,39%
Capitalization 1 610 M 2 145 M 2 147 M
EV / Sales 2021 8,83x
EV / Sales 2022 8,10x
Nbr of Employees 3 472
Free-Float 30,8%
Chart GLOBALDATA PLC
Duration : Period :
GlobalData Plc Technical Analysis Chart | DATA | GB00B87ZTG26 | MarketScreener
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1 365,00 GBX
Average target price 1 735,00 GBX
Spread / Average Target 27,1%
EPS Revisions
Managers and Directors
Michael Thomas Danson Chief Executive Officer & Director
Sally Kate Miranda Johnson Chief Financial Officer
Murray Legg Independent Non-Executive Chairman
Peter Martin Harkness Independent Non-Executive Director
Catherine Birkett Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GLOBALDATA PLC0.00%2 145
S&P GLOBAL INC.38.27%111 653
RELX PLC28.81%60 381
THOMSON REUTERS CORPORATION48.10%59 512
MSCI INC.39.08%52 984
EQUIFAX INC.44.03%34 583